164 related articles for article (PubMed ID: 9154963)
21. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC
Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645
[TBL] [Abstract][Full Text] [Related]
22. Lasofoxifene enhances vaginal mucus formation without causing hypertrophy and increases estrogen receptor beta and androgen receptor in rats.
Wang XN; Simmons HA; Salatto CT; Cosgrove PG; Thompson DD
Menopause; 2006; 13(4):609-20. PubMed ID: 16837883
[TBL] [Abstract][Full Text] [Related]
23. Estrogenic and antiestrogenic effects of raloxifene on collagen metabolism in breast cancer MCF-7 cells.
Wołczynski S; Surazyński A; Swiatecka J; Pałka J
Gynecol Endocrinol; 2001 Jun; 15(3):225-33. PubMed ID: 11447735
[TBL] [Abstract][Full Text] [Related]
24. Raloxifene: a selective estrogen receptor modulator.
Scott JA; Da Camara CC; Early JE
Am Fam Physician; 1999 Sep; 60(4):1131-9. PubMed ID: 10507743
[TBL] [Abstract][Full Text] [Related]
25. Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release.
Kansra S; Yamagata S; Sneade L; Foster L; Ben-Jonathan N
Mol Cell Endocrinol; 2005 Jul; 239(1-2):27-36. PubMed ID: 15950373
[TBL] [Abstract][Full Text] [Related]
26. Expression profiling of rat femur revealed suppression of bone formation genes by treatment with alendronate and estrogen but not raloxifene.
Helvering LM; Liu R; Kulkarni NH; Wei T; Chen P; Huang S; Lawrence F; Halladay DL; Miles RR; Ambrose EM; Sato M; Ma YL; Frolik CA; Dow ER; Bryant HU; Onyia JE
Mol Pharmacol; 2005 Nov; 68(5):1225-38. PubMed ID: 16079270
[TBL] [Abstract][Full Text] [Related]
27. Effects of 3-phenyl-4-[[4-[2-(1-piperidinyl)ethoxy]phenyl]methyl]- 2H-1-benzopyran-7-ol (CHF 4056), a novel nonsteroidal estrogen agonist/antagonist, on reproductive and nonreproductive tissue.
Galbiati E; Caruso PL; Amari G; Armani E; Ghirardi S; Delcanale M; Civelli M
J Pharmacol Exp Ther; 2002 Mar; 300(3):802-9. PubMed ID: 11861784
[TBL] [Abstract][Full Text] [Related]
28. Effects of tamoxifen and raloxifene on normal human endometrial cells in an organotypic in vitro model.
Bläuer M; Heinonen PK; Rovio P; Ylikomi T
Eur J Pharmacol; 2008 Sep; 592(1-3):13-8. PubMed ID: 18638473
[TBL] [Abstract][Full Text] [Related]
29. Molecular determinants of tissue selectivity in estrogen receptor modulators.
Grese TA; Sluka JP; Bryant HU; Cullinan GJ; Glasebrook AL; Jones CD; Matsumoto K; Palkowitz AD; Sato M; Termine JD; Winter MA; Yang NN; Dodge JA
Proc Natl Acad Sci U S A; 1997 Dec; 94(25):14105-10. PubMed ID: 9391160
[TBL] [Abstract][Full Text] [Related]
30. Endocrine and antiprostatic effects of raloxifene (LY156758) in the male rat.
Neubauer BL; Best KL; Clemens JA; Gates CA; Goode RL; Jones CD; Laughlin ME; Shaar CJ; Toomey RE; Hoover DM
Prostate; 1993; 23(3):245-62. PubMed ID: 8234067
[TBL] [Abstract][Full Text] [Related]
31. Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone.
Willson TM; Norris JD; Wagner BL; Asplin I; Baer P; Brown HR; Jones SA; Henke B; Sauls H; Wolfe S; Morris DC; McDonnell DP
Endocrinology; 1997 Sep; 138(9):3901-11. PubMed ID: 9275080
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of the major metabolites of raloxifene as modulators of tissue selectivity.
Dodge JA; Lugar CW; Cho S; Short LL; Sato M; Yang NN; Spangle LA; Martin MJ; Phillips DL; Glasebrook AL; Osborne JJ; Frolik CA; Bryant HU
J Steroid Biochem Mol Biol; 1997 Apr; 61(1-2):97-106. PubMed ID: 9328215
[TBL] [Abstract][Full Text] [Related]
33. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats.
Sato M; Rippy MK; Bryant HU
FASEB J; 1996 Jun; 10(8):905-12. PubMed ID: 8666168
[TBL] [Abstract][Full Text] [Related]
34. Effects of the novel orally active antiestrogen TZE-5323 on experimental endometriosis.
Saito T; Yoshizawa M; Yamauchi Y; Kinoshita S; Fujii T; Mieda M; Sone H; Yamamoto Y; Koizumi N
Arzneimittelforschung; 2003; 53(7):507-14. PubMed ID: 12918217
[TBL] [Abstract][Full Text] [Related]
35. Estrogenic triarylethylene acetic acids: effect of structural variation on estrogen receptor affinity and estrogenic potency and efficacy in MCF-7 cells.
Ruenitz PC; Bourne CS; Sullivan KJ; Moore SA
J Med Chem; 1996 Nov; 39(24):4853-9. PubMed ID: 8941399
[TBL] [Abstract][Full Text] [Related]
36. (S)-(+)-4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)-ethoxy]phenyl]-2H-1-benzopyran-3-yl]-phenyl 2,2-dimethylpropanoate (EM-800): a highly potent, specific, and orally active nonsteroidal antiestrogen.
Gauthier S; Caron B; Cloutier J; Dory YL; Favre A; Larouche D; Mailhot J; Ouellet C; Schwerdtfeger A; Leblanc G; Martel C; Simard J; Mérand Y; Bélanger A; Labrie C; Labrie F
J Med Chem; 1997 Jul; 40(14):2117-22. PubMed ID: 9216828
[No Abstract] [Full Text] [Related]
37. Clinical effects of raloxifene hydrochloride in women.
Khovidhunkit W; Shoback DM
Ann Intern Med; 1999 Mar; 130(5):431-9. PubMed ID: 10068418
[TBL] [Abstract][Full Text] [Related]
38. Distinct mechanisms of action of selective estrogen receptor modulators in breast and osteoblastic cells.
Nuttall ME; Stroup GB; Fisher PW; Nadeau DP; Gowen M; Suva LJ
Am J Physiol Cell Physiol; 2000 Nov; 279(5):C1550-7. PubMed ID: 11029302
[TBL] [Abstract][Full Text] [Related]
39. Selective estrogen receptor modulators: an alternative to hormone replacement therapy.
Bryant HU; Dere WH
Proc Soc Exp Biol Med; 1998 Jan; 217(1):45-52. PubMed ID: 9421206
[TBL] [Abstract][Full Text] [Related]
40. Antioestrogenic and antitumour activities of a series of non-steroidal antioestrogens.
Wakeling AE; Valcaccia B
J Endocrinol; 1983 Dec; 99(3):455-64. PubMed ID: 6644236
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
